Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [2193]
News [4496]
Articles [112]
Editorials [23]
Conferences [171]
elearning [18]
The 2022 OncoAlert Colloquium Day 4: ESGO Sessions and Gynaecological Oncology
Dr Gilberto Morgan - Skåne University Hospital in Lund, Sweden
The 2022 OncoAlert Colloquium Day 4: ESGO Sessions and Gynaecological Oncology ( Dr Gilberto Morgan - Skåne University Hospital in Lund, Sweden )
31 Jan 2023
The 2022 OncoAlert Colloquium Day 3: Lung Cancer
Dr Gilberto Morgan - Skåne University Hospital in Lund, Sweden
The 2022 OncoAlert Colloquium Day 3: Lung Cancer ( Dr Gilberto Morgan - Skåne University Hospital in Lund, Sweden )
31 Jan 2023
The 2022 OncoAlert Colloquium Day 2: GU Oncology
Dr Gilberto Morgan - Skåne University Hospital in Lund, Sweden
The 2022 OncoAlert Colloquium Day 2: GU Oncology ( Dr Gilberto Morgan - Skåne University Hospital in Lund, Sweden )
31 Jan 2023
The 2022 OncoAlert Colloquium Day 1: Breast Cancer
Dr Gilberto Morgan - Skåne University Hospital in Lund, Sweden
The 2022 OncoAlert Colloquium Day 1: Breast Cancer ( Dr Gilberto Morgan - Skåne University Hospital in Lund, Sweden )
30 Jan 2023
10 fundamental health literacy principles for the public to understand when...
Dr Bishal Gyawali - Queen's University, Kingston, Canada
10 fundamental health literacy principles for the public to understand when reading health-related articles ( Dr Bishal Gyawali - Queen's University, Kingston, Canada )
25 Jan 2023
The placebo effect in oncology trials and the criteria for approving drugs
Dr Bishal Gyawali - Queen's University, Kingston, Canada
The placebo effect in oncology trials and the criteria for approving drugs ( Dr Bishal Gyawali - Queen's University, Kingston, Canada )
18 Jan 2023
ZUMA-7: Axi-cel is superior to standard of care across common prognostic...
Dr Fred Locke - Moffitt Cancer Center, Tampa, USA
ZUMA-7: Axi-cel is superior to standard of care across common prognostic subgroups in R/R LBCL ( Dr Fred Locke - Moffitt Cancer Center, Tampa, USA )
23 Dec 2022
Shorter time from leukapheresis to infusion of axi-cel corresponds to better CR...
Dr Fred Locke - Moffitt Cancer Center, Tampa, USA
Shorter time from leukapheresis to infusion of axi-cel corresponds to better CR and OS in r/r LBCL patients ( Dr Fred Locke - Moffitt Cancer Center, Tampa, USA )
23 Dec 2022
T-DXd demonstrates high levels of efficacy in patients with HER2+ unresectable...
Dr Ian Krop - Yale Cancer Center, Connecticut, USA
T-DXd demonstrates high levels of efficacy in patients with HER2+ unresectable and/or mBC previously treated with T-DM1 ( Dr Ian Krop - Yale Cancer Center, Connecticut, USA )
23 Dec 2022
ASH 2022: Multiple myeloma roundup
Dr Thomas Martin - UCSF Medical Centre, San Francisco, USA
ASH 2022: Multiple myeloma roundup ( Dr Thomas Martin - UCSF Medical Centre, San Francisco, USA )
22 Dec 2022
Gemtuzumab ozogamicin plus chemotherapy improves outcomes in intermediate-risk...
Dr Eunice Wang - Roswell Park Comprehensive Cancer Center, New York, USA
Gemtuzumab ozogamicin plus chemotherapy improves outcomes in intermediate-risk cytogenetic AML ( Dr Eunice Wang - Roswell Park Comprehensive Cancer Center, New York, USA )
22 Dec 2022
Comment: POLAR gene profile can identify which patients can safely avoid...
Prof Christos Markopoulos- National and Kapodistrian University of Athens...
Comment: POLAR gene profile can identify which patients can safely avoid radiation therapy after breast-conserving surgery ( Prof Christos Markopoulos- National and Kapodistrian University of Athens, Athens, Greece )
22 Dec 2022

More from ecancer

Register with ecancer to receive our newsletter

Register here

Explore patient resources at ecancerpatient

Visit site

Find out more about ecancer and the work we do

About ecancer

Support ecancer's work by making a donation